Nishiyama M, Noso Y, Hirabayashi N, Yamaguchi M, Toge T, Niimoto M, Hattori T
Jpn J Surg. 1986 Jul;16(4):257-61. doi: 10.1007/BF02470934.
Fifty-three tumor specimens, including thirty-one stomach and seven esophageal cancers, were examined to determine the individual tumor sensitivity to chemotherapeutic agents. Using the subrenal capsule assay (SRC assay), tumor specimens were implanted under the renal capsule of male, 8 week old ddY mice, after cutting the tissues into 1.5 mm cubed fragments. Following the implantations, chemotherapeutic agents were injected daily for 3 days and the relative variations of tumor weights were calculated. An 84.9 per cent of the total evaluability rate was obtained and implanted tumor specimens responded to chemotherapeutic agents in 26.7 per cent. The correlation rate between tumor sensitivity in SRC assay and clinical responses was obtained in 72.9 per cent. The predictive accuracy rate of the clinical responses was 50.0 per cent, while 100 per cent of the prediction rate of clinical resistance was obtained. With regard to upper gastro-intestinal cancers, 83.9 per cent of the evaluability rate and 18.2 per cent of response rate in SRC assay were obtained. These results indicate that this assay is equivalent to other procedures for predicting individual tumor sensitivity.
对53个肿瘤标本进行了检测，其中包括31个胃癌标本和7个食管癌标本，以确定各个肿瘤对化疗药物的敏感性。采用肾包膜下测定法（SRC测定法），将肿瘤组织切成1.5立方毫米的碎片后，植入8周龄雄性ddY小鼠的肾包膜下。植入后，连续3天每天注射化疗药物，并计算肿瘤重量的相对变化。总可评估率为84.9%，植入的肿瘤标本对化疗药物有反应的占26.7%。SRC测定法中的肿瘤敏感性与临床反应之间的相关率为72.9%。临床反应的预测准确率为50.0%，而临床耐药的预测率为100%。对于上消化道癌，SRC测定法的可评估率为83.9%，反应率为18.2%。这些结果表明，该测定法与其他预测个体肿瘤敏感性的方法相当。
